This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Enhancer of zeste homolog 2 (EZH2); SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily b member 1 (SMARCB1; SNF5)	<p>Cell culture and mouse studies identified an EZH2 inhibitor that could help treat <i>SMARCB1</i> mutant malignant rhabdoid tumors (MRTs). In <i>SMARCB1</i> mutant MRT cells, the EZH2 inhibitor EPZ-6438 blocked proliferation with nanomolar IC₅₀ values. In mouse xenograft models for <i>SMARCB1</i> mutant MRT, oral EPZ-6438 for 21 days caused tumor regression without regrowth 32 days after inhibitor cessation. Next steps could include testing the EZH2 inhibitor in additional models for cancer.</p> <p>Epizyme Inc. and Eisai Co. Ltd. have EPZ-6438 in preclinical testing to treat lymphoma.</p> <p>SciBX 6(19); doi:10.1038/scibx.2013.463 Published online May 16, 2013</p>	Patent and licensing status unavailable	<p>Knutson, S.K. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online April 25, 2013; doi:10.1073/pnas.1303800110</p> <p>Contact: Heike Keilhack, Epizyme Inc., Cambridge, Mass. e-mail: hkeilhack@epizyme.com</p>